How to Stop Leaking Blood Vessels: Causes & Treatments

Leaking blood vessels are not a single disease but a shared problem across dozens of conditions, from diabetic eye disease to severe infections to trauma. The leak happens when the thin lining of cells inside every blood vessel loses its seal, allowing fluid, proteins, or blood cells to escape into surrounding tissue. Stopping that leak depends entirely on why it started, and treatments range from eye injections that block a single signaling molecule to emergency catheter procedures that physically plug a damaged artery.

How the Vessel Wall Normally Stays Sealed

Every blood vessel is lined with a single layer of endothelial cells that act as a selective barrier. These cells are not fused together into a solid sheet. Instead, they are held side by side by protein complexes called adherens junctions, which function like molecular Velcro between neighboring cells.¹ When those junctions are intact, only small molecules and carefully regulated amounts of fluid pass through. When they pull apart, the barrier breaks down and larger molecules leak out.

Sitting on top of the endothelial cells is a sugary mesh called the glycocalyx, a gel-like coating that lines the entire inside surface of every blood vessel. This layer helps regulate what gets through the vessel wall, acts as a buffer against inflammation, and even senses blood flow. In critical illness, the glycocalyx can be stripped away, and that degradation alone is enough to trigger significant vascular leakage.² Both layers need to be functional for vessels to hold their contents properly.

What Makes Blood Vessels Leak

The causes fall into a few broad categories: signaling molecules that actively pry open the barrier, infections and inflammation that destroy it, physical forces that wear it down, and genetic conditions that leave it vulnerable.

VEGF and Inflammatory Signals

Vascular endothelial growth factor, usually called VEGF, is the most studied driver of vascular leakage. The body produces it to grow new blood vessels, but it also dramatically increases permeability. In animal studies, VEGF triggers a chain reaction: it activates an enzyme that produces nitric oxide in the vessel wall, which causes the vessel to dilate, and simultaneously disrupts VE-cadherin, the key protein holding endothelial cells together.³ The result is both wider vessels and gaps between the cells lining them.

VEGF does not work alone. A protein called Angiopoietin-2 cooperates with VEGF to destabilize the vessel wall. Normally, a receptor on endothelial cells called Tie2 is kept active by Angiopoietin-1, and that activation acts like a molecular brake on inflammation and leakage. Angiopoietin-2 blocks that receptor, releasing the brake.⁴ When both Angiopoietin-2 and VEGF are elevated at the same time, vessel instability and leakage accelerate.⁵

Bradykinin, a small peptide hormone, is another potent trigger. It directly increases vascular permeability and is the central mediator in hereditary angioedema, a genetic condition where episodes of severe swelling occur because the body cannot properly regulate bradykinin levels.⁶

Infections and Sepsis

Severe infections are among the most dangerous causes of vascular leakage. In sepsis, the body’s overwhelming inflammatory response degrades the glycocalyx and activates endothelial cells, opening gaps in the vessel wall.⁷ Dengue fever is a textbook example: endothelial dysfunction leading to plasma leakage is the hallmark of severe dengue, and what separates a manageable infection from life-threatening dengue shock syndrome.⁸ Both sepsis and severe dengue share common features of glycocalyx destruction, endothelial activation, and barrier breakdown.⁹

Blood Flow Patterns and Shear Stress

The physical force of blood flowing over endothelial cells matters too. Steady, laminar flow actually helps maintain the barrier. But at branch points and curves in arteries, blood flow becomes turbulent and creates low or oscillating shear stress on the vessel wall. This abnormal flow impairs the glycocalyx, disrupts the cytoskeleton inside endothelial cells, and weakens junctions between them, all of which increase permeability.¹⁰ The disturbed flow can also push endothelial cells toward a pro-inflammatory state, increasing oxidative stress and metabolic dysfunction, which further promotes early atherosclerotic lesions.¹¹ This is one reason atherosclerosis tends to develop at arterial branch points rather than in straight segments.

Anti-VEGF and Dual-Pathway Therapies

The most refined treatments for vascular leakage target the molecular signals that cause it. Anti-VEGF drugs, injected directly into the eye, have transformed the treatment of retinal diseases where leaking vessels threaten vision, including diabetic macular edema and the wet form of age-related macular degeneration.¹² By neutralizing VEGF before it can bind to receptors on endothelial cells, these drugs reduce the signal that opens up the barrier.

A newer approach goes further. Faricimab is a bispecific antibody that blocks both VEGF-A and Angiopoietin-2 simultaneously. Because it hits both pathways driving vessel instability, data from six phase III trials suggest it has a greater effect on reducing markers of vascular leakage than blocking VEGF alone, while also addressing neovascularization and inflammation.¹³ In the BOULEVARD trial, researchers found that simultaneous inhibition of Angiopoietin-2 and VEGF-A restored retinal structure and function better than VEGF inhibition alone, particularly in patients with persistent diabetic macular edema.¹⁴ Real-world data have further shown that this dual approach achieves comparable visual and anatomical results with fewer injections, reducing the burden on patients.¹⁵

Corticosteroids and Bradykinin-Targeted Drugs

Corticosteroids have a long track record for reducing vascular leakage, particularly in the eye. In an animal model of retinal barrier breakdown, systemic dexamethasone given for three days completely blocked VEGF-induced leakage, and a single intravitreal dose of triamcinolone acetonide stopped VEGF-driven retinal and iris leakage for 45 days.¹⁶ In clinical practice, steroid implants in the eye remain an option when anti-VEGF drugs are not enough, though they carry risks like elevated eye pressure and cataracts.

For hereditary angioedema, treatments target the bradykinin pathway directly. The underlying problem in most cases is a deficiency or malfunction of C1 esterase inhibitor, a protein that normally keeps the kallikrein-kinin system in check. When that control fails, excess bradykinin is produced, driving episodic fluid leakage into tissues.¹⁷ Treatments include C1 inhibitor replacement, kallikrein inhibitors that prevent bradykinin from being generated in the first place, and bradykinin receptor blockers. These represent one of the clearest examples of stopping vascular leakage by shutting off the specific molecular trigger.

The Body’s Own Barrier-Repair System

Not all the body’s signals promote leakage. Sphingosine-1-phosphate, a lipid molecule released by activated platelets and carried in the blood on HDL particles, actively strengthens the endothelial barrier. Research suggests that HDL-bound sphingosine-1-phosphate is essential for maintaining the barrier under normal conditions, and that it may be protective when barrier function is threatened by disease.¹⁸ In cell experiments, sphingosine-1-phosphate drives the formation of a ring of structural protein around the edges of endothelial cells and brings adhesion proteins to the cell borders, physically tightening the seal between cells.¹⁹ Studies also show that this molecule is a major barrier-protective substance produced by human platelets.²⁰

This is relevant because it explains why conditions that lower HDL or reduce platelet function could indirectly worsen vascular leakage, and it opens the door to future therapies that boost this natural repair pathway rather than just blocking the damage signals.

Emergency and Surgical Approaches

When vessels are physically damaged rather than molecularly destabilized, stopping the leak requires mechanical solutions. Transcatheter embolization is a technique where an interventional radiologist threads a catheter into the damaged vessel and deploys materials to seal it off from the inside. It plays a major role in treating traumatic vascular injuries to organs and limbs.²¹ It is also used for postoperative bleeding and gastrointestinal hemorrhage. For post-surgical bleeding, one study of transcatheter embolization reported technical success in about 96% of procedures and clinical success in roughly 82% of patients.²² For gastrointestinal bleeding, a tissue adhesive called NBCA has proven effective as a primary embolization agent for both upper and lower GI bleeds.²³

At the wound surface, fibrin sealants work through a different principle. These products combine fibrinogen and thrombin to create an artificial clot at the site of injury. They can function as a hemostat that activates clotting, a sealant that physically blocks blood from escaping, and an adhesive that holds tissues together. Fibrin sealant remains the only commercially available FDA-approved material that works across all three of those categories.²⁴ Tranexamic acid takes a different tack: rather than forming a new clot, it stabilizes the clot that has already formed by blocking the enzyme that breaks fibrin down. This makes it useful in trauma, surgery, and heavy menstrual bleeding, where the problem is not that a clot cannot form but that it dissolves too quickly.²⁵

Nutritional and Plant-Based Support

Vitamin C plays a structural role in vessel integrity that goes beyond its reputation as an antioxidant. It is required for the synthesis of type IV collagen, the main structural protein in the basement membrane that sits underneath the endothelial cells. Without enough vitamin C, that foundation weakens. In addition to collagen production, vitamin C stimulates endothelial cell growth, inhibits programmed cell death in those cells, and helps preserve nitric oxide, the molecule that regulates blood flow.²⁶ It also helps stabilize the extracellular matrix and regulate lipid metabolism.²⁷ Frank vitamin C deficiency, known as scurvy, makes the classic case: the first visible symptoms are bleeding gums and easy bruising from fragile, leaking capillaries.

On the pharmaceutical-supplement border sits micronized purified flavonoid fraction, a formulation of 90% diosmin and 10% hesperidin derived from citrus. It improves venous tone, enhances lymphatic drainage, and reduces capillary hyperpermeability by protecting the microcirculation from inflammatory damage.²⁸ In animal models, it reduces leukocyte adhesion to the vessel wall and prevents endothelial damage in response to blood-flow disruption, which may explain why it helps with edema and other symptoms of chronic venous insufficiency.²⁹ This product is widely prescribed in Europe and parts of Asia for venous disease and hemorrhoids, though it remains less well known in the United States.

Where Research Is Heading

The fact that vascular leakage is a problem in such different diseases, from eye conditions to cancer to infections, has pushed researchers toward more creative solutions. One emerging concept involves nanoparticles designed to first exploit and then repair endothelial leakiness. A recent study described a nanoparticle coated in cell membrane and loaded with Angiopoietin-1, the natural protein that stabilizes vessels. These particles can penetrate a leaky endothelial barrier to deliver cancer drugs, and once inside, they release Angiopoietin-1 to restore the barrier behind them, essentially closing the door after entering.³⁰ In animal experiments, this approach both delivered therapy and restricted tumor metastasis by limiting the leaky vessels that cancer cells use to spread.

On the diagnostic side, better tools for measuring leakage are being developed. A technique called ExCEL-OCT uses optical imaging combined with injected contrast particles to map vascular leakage in 3D within the retina of living mice, offering spatial detail that older methods could not achieve.³¹ If adapted for human use, methods like this could let clinicians spot early leakage before it causes visible damage, making it possible to intervene sooner. The overall direction is clear: the field is shifting from treating the consequences of vascular leakage, like draining fluid or mopping up swelling, toward understanding the specific molecular failures well enough to fix the barrier itself.